Page 100 - Read Online

tumors benefit more than those with a poor arterial carcinoma. Cancer Biol Ther 2008;7:496-501.
supply of tumors. Further prospective studies need 9. Horger M, Lauer UM, Schraml C, Berg CP, Koppenhöfer U, Claussen
CD, Gregor M, Bitzer M. Early MRI response monitoring of patients
to be conducted to reveal the relationship between with advanced hepatocellular carcinoma under treatment with the
the degree of tumor enhancement in the arterial multikinase inhibitor sorafenib. BMC Cancer 2009;9:208.
phase and the prognosis of HCC patients treated 10. Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O. The
with sorafenib therapy. diffusion-weighted imaging perfusion fraction f is a potential marker
of sorafenib treatment in advanced hepatocellular carcinoma: a pilot
study. Eur Radiol 2011;21:281-90.
Financial support and sponsorship 11. Marrero JA. Staging systems for hepatocellular carcinoma: should we
This work is supported by Second Military Medical all use the BCLC system? J Hepatol 2006;44:630-2.
University Funds for Young Scholar (2011QN23) and 12. Li JP, Zhao DL, Jiang HJ, Huang YH, Li DQ, Wan Y, Liu XD, Wang
National Natural Science Foundation (81301878). JE. Assessment of tumor vascularization with functional computed
tomography perfusion imaging in patients with cirrhotic liver disease.
Hepatobiliary Pancreat Dis Int 2011;10:43-9.
Conflicts of interest 13. Ippolito D, Sironi S, Pozzi M, Antolini L, Ratti L, Alberzoni C, Leone
There are no conflicts of interest. EB, Meloni F, Valsecchi MG, Fazio F. Hepatocellular carcinoma
in cirrhotic liver disease: functional computed tomography with
REFERENCES perfusion imaging in the assessment of tumor vascularization. Acad
Radiol 2008;15:919-27.
1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 14. Asayama Y, Yoshimitsu K, Nishihara Y, Irie H, Aishima S, Taketomi
2012;379:1245-55. A, Honda H. Arterial blood supply of hepatocellular carcinoma and
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis histologic grading: radiologic-pathologic correlation. AJR Am J
and treatment of hepatocellular carcinoma. Gastroenterology Roentgenol 2008;190:W28-34.
2008;134:1752-63. 15. Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de K, Irie H, Aibe H, Shimada M, Masuda K. Sequential hemodynamic
Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta change in hepatocellular carcinoma and dysplastic nodules: CT
C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath angiography and pathologic correlation. AJR Am J Roentgenol
I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, 2002;178:885-97.
Bruix J; SHARP Investigators Study Group. Sorafenib in advanced 16. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J
hepatocellular carcinoma. N Engl J Med 2008;359:378-90. Med 1971;285:1182-6.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, 17. Senger DR, Van De Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK,
Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability
Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev
in patients in the Asia-Pacific region with advanced hepatocellular 1993;12:303-24.
carcinoma: a phase III randomised, double-blind, placebo-controlled 18. Von Marschall Z, Cramer T, Höcker M, Finkenzeller G, Wiedenmann
trial. Lancet Oncol 2009;10:25-34. B, Rosewicz S. Dual mechanism of vascular endothelial growth factor
5. Cyran CC, von Einem JC, Paprottka PM, Schwarz B, Ingrisch M, upregulation by hypoxia in human hepatocellular carcinoma. Gut
Dietrich O, Hinkel R, Bruns CJ, Clevert DA, Eschbach R, Reiser 2001;48:87-96.
MF, Wintersperger BJ, Nikolaou K. Dynamic contrast-enhanced 19. Kanematsu M, Osada S, Amaoka N, Goshima S, Kondo H, Nishibori H,
computed tomography imaging biomarkers correlated with Kato H, Matsuo M, Yokoyama R, Hoshi H, Moriyama N. Expression
immunohistochemistry for monitoring the effects of sorafenib on of vascular endothelial growth factor in hepatocellular carcinoma and
experimental prostate carcinomas. Invest Radiol 2012;47:49-57.
6. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, the surrounding liver: correlation with angiographically assisted CT.
Manchen E, Mitchell M, Ratain MJ, Stadler WM. Dynamic contrast- AJR Am J Roentgenol 2004;183:1585-93.
enhanced magnetic resonance imaging pharmacodynamic biomarker 20. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito
study of sorafenib in metastatic renal carcinoma. J Clinl Oncol Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai
2008;26:4572-8. K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa
7. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, K, Kamada T. Expression of vascular permeability factor/vascular
Cheng AL, Shih TT. Dynamic contrast-enhanced magnetic resonance endothelial growth factor in human hepatocellular carcinoma. Cancer
imaging biomarkers predict survival and response in hepatocellular Res 1996;56:3004-9.
carcinoma patients treated with sorafenib and metronomic tegafur/ 21. Kwak BK, Shim HJ, Park ES, Kim SA, Choi D, Lim HK, Park CK,
uracil. J Hepatol 2011;55:858-65. Chung JW, Park JH. Hepatocellular carcinoma: correlation between
8. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz vascular endothelial growth factor level and degree of enhancement
B, Schnall MD, O’Dwyer PJ. Pilot study of DCE-MRI to predict by multiphase contrast-enhanced computed tomography. Invest Radiol
progression-free survival with sorafenib therapy in renal cell 2001;36:487-92.

Hepatoma Research | Volume 2 | April 1, 2016 91